Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2005

View Archived Issues

DOV presents pipeline review

Aurora kinase inhibitor MLN-8054 begins phase I study

Vernalis signs Apokyn licensing agreements

Array BioPharma and Ono form drug discovery collaboration

Emisphere cleared for phase II oral insulin study in India

Further funding for obesity drug development at Adipogen

Mount Sinai School of Medicine advances tumor immunization into clinic

Progress of gene therapy for the treatment of critical limb ischemia

Targeting GlyT1: potential new type of antipsychotic

FDA grants fast track status to Provenge

Remicade sBLA for plaque psoriasis accepted for filing

Recent patents describe novel analgesic agents

Sumitomo prepares and tests sulfonamide derivatives for hyperlipidemia, arteriosclerosis, etc.

University of California develops cidofovir derivatives with antiviral properties

ISIS-301012 begins phase II statin combination study for high cholesterol

Novel antithrombotic agents revealed in patent literature

European phase III trial of Davanat cleared to begin

Good safety profile of single-dose PBT-2 in healthy volunteers

ISA-247 reported effective in moderate to severe psoriasis

New data on the effects, safety and pharmacokinetics of estetrol

Panitumumab improves progression-free survival of patients with metastatic colorectal cancer

Clinical evidence supports the use of rasagiline in Parkinson's disease

Investigators link various genes with the development of dyslexia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...